To assess effect of cholecalciferol on blood pressure (BP) variability in women with arterial hypertension (AH) in premenopausal and early postmenopausal periods who received 25 (OH)D supplementation.Design and method:
We investigated 102 women with AH stage II risk 3 aged 50 (48;53) years: 50 females in premenopausal period – group I and 52 females in early postmenopausal period – group II. Serum level of 25 (OH)D was determined by the immunoenzymatic assay. In groups I and II we identified subgroups with the level of 25 (OH)D <30 ng/ml: subgroup IB (n = 25) and subgroup IIB (n = 21) respectively, in which antihypertensive therapy was supplemented with cholecalciferol 2,000 IU/day for 3 months. In subgroups IA (n = 25) and IIA (n = 31) cholecalciferol was not administered. BP variability were calculated as the mean root square deviation from average values of systolic and diastolic BP (SBP/DBP) during day/night while conducting 24-hour BP monitoring.Results:
At baseline the level of 25 (OH)D was lower (p < 0,05) in subgroups IB (19,3 ± 8,5 ng/ml) and IIB (18,2 ± 9,5 ng/ml) than in the comparable subgroups IA (26,7 ± 11,5 ng/ml) and IIA (27,4 ± 10,5 ng/ml). After supplementation the level of 25 (OH)D increased (p < 0,001) in subgroup IB (37,28 ± 11,97 ng/ml) and in subgroup IIB (36,4 ± 10,0 ng/ml), and became higher (p < 0,001) than in the comparable subgroups IA and IIA. At baseline subgroups IA and IB did not differ (p > 0,05) by SBP/DBP variability during day/night. After the therapy SBP variability at nighttime became lower (p < 0,02) in group IB as compared to group IA (12 (10;14) mmHg and 15 (11;18) mmHg). In subgroup IIB indices of SPB variability at daytime were higher (p = 0,04) at baseline than in group IIA (36,0 (29,0;43,0) mmHg versus 25,0 (22,0;38,0) mmHg). Following the therapy dynamics of SBP variability at daytime was highest (p < 0,05) in subgroup IIB (-17,61 ± 13,15 mmHg) as compared to the comparable subgroup IIA (-8,17 ± 9,06 mmHg), as well as to subgroups IB (-9,32 ± 15,85 mmHg) and IA (-7,85 ± 8,35 mmHg) correspondingly. We established significant contribution of cholecalciferol to dynamics of SBP variability at daytime: F = 3,95, p = 0,05.Conclusions:
Correction of 25 (OH)D level by intake of cholecalciferol 2000 IU/day for 3 months leads to reduction of BP variability in women with AH.